← Eichor
Condition: Car T Therapy Complications Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Car T Therapy Complications

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells
Phase 1 · 1 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT06305299A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
Phase 1 · 14 location(s) · CRISPR Therapeutics · NCT06925542RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic
Phase 1/Phase 2 · 23 location(s) · Cabaletta Bio · NCT06121297A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Gynecologic Cancer
Phase 1 · 1 location(s) · Chongqing Precision Biotech Co., Ltd · NCT06215950A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite I
Phase 2 · 96 location(s) · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · NCT07015983Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Includi
Phase 1 · 1 location(s) · National Cancer Institute (NCI) · NCT06885697A Study of Anti-CD19/BCMA Universal CAR-T Cell Therapy RD06-05 in Patients With Autoimmune Diseases.
EARLY_Phase 1 · 1 location(s) · Nanjing Bioheng Biotech Co., Ltd. · NCT07203404A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combinatio
Phase 1 · 5 location(s) · Regeneron Pharmaceuticals · NCT06469281CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B Cell Mediated Autoimmune Disease
Phase 1 · 1 location(s) · The Children's Hospital of Zhejiang University School of Med · NCT07305116A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Disease
Phase 1 · 28 location(s) · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · NCT07115745Tissue Study in Patients Undergoing CAR-T Cell Therapy (CAR_21_01)
Phase N/A · 1 location(s) · IRCCS Azienda Ospedaliero-Universitaria di Bologna · NCT04892433A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumor
Phase 1/Phase 2 · 10 location(s) · A2 Biotherapeutics Inc. · NCT06682793A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With
Phase 1 · 14 location(s) · Allogene Therapeutics · NCT07085104CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors
Phase 1 · 1 location(s) · Chongqing Precision Biotech Co., Ltd · NCT07181720A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors
Phase 1 · 1 location(s) · Chongqing Precision Biotech Co., Ltd · NCT06010875A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE
Phase 1/Phase 2 · 18 location(s) · AstraZeneca · NCT06897930Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune Disease
EARLY_Phase 1 · 1 location(s) · The Children's Hospital of Zhejiang University School of Med · NCT07507201A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer
Phase 1 · 4 location(s) · Outpace Bio, Inc. · NCT07030907Early Integration of Palliative and Supportive Care in Cellular Therapy
NA · 1 location(s) · Alberta Health Services, Calgary · NCT05190653Safety and Efficacy of CD19 Chimeric Antigen Receptor T-Cell (CAR-T) in the Treatment of Refractory Membranous Nephropat
Phase 1 · 1 location(s) · The First Affiliated Hospital of Air Force Medicial Universi · NCT07266181CAR-T Cell Therapy for Desensitization in Kidney Transplantation
Phase 1 · 3 location(s) · National Institute of Allergy and Infectious Diseases (NIAID · NCT06056102Intervention of Bladder Cancer by CAR-T
Phase 1/Phase 2 · 1 location(s) · Shenzhen Geno-Immune Medical Institute · NCT03185468Sequential CD146 and GPC3 CAR-T Cell Therapy in Advanced Ovarian Cancer
Phase 1/Phase 2 · 1 location(s) · Essen Biotech · NCT07067255KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
Phase 1 · 2 location(s) · Christian Hinrichs · NCT05483491Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Essen Biotech · NCT07410494GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours
Phase 1 · 2 location(s) · Canadian Cancer Trials Group · NCT07297667Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE)
Phase 1/Phase 2 · 1 location(s) · Essen Biotech · NCT06350110SELECT-SLE: Biomarker-Guided CAR-T Target Selection for Refractory Lupus
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07523542IVIG for Infection Prevention After CAR-T-Cell Therapy
Phase 2 · 7 location(s) · Fred Hutchinson Cancer Center · NCT05952804Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)
Phase 1 · 2 location(s) · Children's National Research Institute · NCT07172958
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.